PERFORMANCE OF CTI COVID 19 50 DAYS AT ÁLVARO ALVIM HOSPITAL

• Autor(a) principal: Ribeiro de Andrade Sodré, Renato
• Data de Publicação: 2020
• Outros Autores: da Silva Rosário, Inês Raquel Alves, Eduardo, Mariana Pompermayer, Rangel, Suellen dos Santos, Martins, Gabriele Maria Viana, Rodrigues, Patricia Rangel
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Científica da Faculdade de Medicina de Campos
• Texto Completo: https://www.fmc.br/ojs/index.php/RCFMC/article/view/426
• topic: COVID19; SAPS3; HIDROXICLOROQUINA; Dexametasona; COVID19. SAPS 3. Hydroxychloroquine. Dexamethasone.; Covid19; SAPS3; HYDROXYCLOROQUINA; Dexamethasone

The severe acute respiratory syndrome - coronavirus (SARS-CoV) - is a highly transmissible and pathogenic virus that appeared in humans at the beginning of the 21st century and gave rise to the first pandemic of the millennium. The most common symptoms observed are cough, fever, headache, prostration, abdominal pain, loss of smell and taste and dyspnea. More severe cases evolve with respiratory failure and secondary bacterial infection. The adequate treatment is still not well defined, with studies of weak methodology that do not guarantee safety to the doctor. The SAPS 3 is an externally validated tool that predicts mortality in the ICU, but it does not cover patients with COVID, and can estimate a mortality that is not real. The objective of this study is to report the performance of ICU COVID of Hospital Escola Álvaro Alvim (HEAA) comparing the mortality obtained with the expected result of SAPS 3, the result shows a mortality of 45% of ICU against 69% of mortality expected by SAPS 3. In this study service, it was chosen not to use hydroxychloroquine, ivermectin and high doses of corticoids. The good result of the sector was adhered to the use of dexamethasone 6 mg/day and early antibiotic therapy in addition to prioritizing protective ventilation and early active or passive pronation.